Markets:

Overview

News

Currencies

International

Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

534.55 -18.60 (-3.36%)

Delayed Quote Updated: 11:42 AM EST, Nov 3, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Vertex Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9

...

69 70 Next >

Vertex: 3 Key Takeaways for Long-Term Investors ↗

Today 7:19 EST

Vertex is betting on nephrology and rare endocrinology to build a fifth and fourth commercial pillar beyond cystic fibrosis.

Via The Motley Fool

Topics Earnings

Vertex (VRTX) Q3 2026 Earnings Call Transcript ↗

Today 1:43 EST

Revenue grew 12% as newer products like CASGEVY and JOURNAVX ramped up significantly.

Via The Motley Fool

Topics Earnings

VRTX Q3 deep dive: Pipeline, product launches, and Crinetics integration shape outlook

Today 0:31 EST

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) reported Q3 2026 results exceeding the market’s revenue expectations, with sales up 11.8% year on year t...

Via StockStory

Vertex Pharmaceuticals (NASDAQ:VRTX) Q3 Earnings: In-Line Revenue, Modest EPS Miss, Raised Guidance and Higher Spending ↗

November 02, 2026

Via Chartmill

Vertex Pharmaceuticals Q3 Earnings Call Highlights ↗

November 02, 2026

Vertex Pharmaceuticals (NASDAQ:VRTX) reported third-quarter 2026 revenue growth of 12% year over year, supported by continued cystic fibrosis franchise growth and contributions from newer products...

Via MarketBeat

Topics Earnings

Vertex Spends Its CF Growth on New Launches: Rapid Earnings Reaction ↗

November 02, 2026

Vertex's cystic fibrosis business is still growing, but the company is pouring those gains into new franchises. Here's what the third quarter shows about the cost of building its next act.

Via The Motley Fool

Vertex Pharmaceuticals’s (NASDAQ:VRTX) Q3 2026 sales top estimates

November 02, 2026

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) reported Q3 2026 results exceeding the market’s revenue expectations, with revenue up 11.8% year on year...

Via StockStory

Vertex Pharmaceuticals earnings: what to look for from VRTX

October 31, 2026

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be announcing earnings results this Monday after market close. Here’s what to expect. Vertex Pharma...

Via StockStory

Topics Artificial Intelligence

3 large-cap stocks with solid fundamentals

October 30, 2026

Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors. However, their sheer size makes it m...

Via StockStory

After-Hours S&P 500 Movers: Mondelez and FedEx Freight Gain, Intel and Reddit Fall ↗

October 29, 2026

Via Chartmill

Topics Stocks

Amgen vs. Vertex Pharmaceuticals: Massive Pharmaceutical Scale vs. Steady Drug Revenue ↗

October 27, 2026

Amgen's quarterly revenue swings between $8.1B and $10.1B, while Vertex climbs steadily from $2.8B to $3.3B—a tale of scale versus trajectory.

Via The Motley Fool

Topics Intellectual Property Lawsuit

I'm Not Worried About a Stock Market Crash, and It's Because I'm Making This 1 Investing Move ↗

October 26, 2026

Here's how I'm staying calm as valuations hit record highs.

Via The Motley Fool

Topics Artificial Intelligence Economy

Forget Casgevy: CRISPR Therapeutics' Heart-Disease Data Could Matter More ↗

October 24, 2026

The company's gene-editing-focused platform looks promising.

Via The Motley Fool

Vertex Pharmaceuticals Gets 96% of Product Sales From Treatments for 1 Disease. Here's Why That's About to Change. ↗

October 24, 2026

Vertex is expanding beyond its cystic fibrosis franchise.

Via The Motley Fool

Vertex Highlights Kidney Pipeline as Povetacicept Cuts Proteinuria 52% in Phase III ↗

October 23, 2026

Vertex Pharmaceuticals (NASDAQ:VRTX) outlined updates across its kidney disease pipeline at the American Society of Nephrology Kidney Week 2026, highlighting data for povetacicept in IgA nephropathy...

Via MarketBeat

S&P 500 Premarket Movers on Oct. 21: Tech Hardware and AI Suppliers Gain, Health Care Declines ↗

October 21, 2026

Via Chartmill

Topics Artificial Intelligence Stocks Supply Chain

AbbVie vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? ↗

October 20, 2026

AbbVie generates $17.8 billion in annual free cash flow but faces patent cliffs, while Vertex boasts a 33% net margin with concentrated cystic fibrosis exposure.

Via The Motley Fool

Topics Intellectual Property

Warren Buffett's Bluntest Warning Yet -- and 3 Stocks Built to Survive It ↗

October 19, 2026

Buffett has warned about "gambling" in the market.

Via The Motley Fool

Topics Intellectual Property Retirement

Where Will CRISPR Therapeutics Stock Be in 2030? ↗

October 18, 2026

The company's expertise in gene editing could lead to more breakthroughs.

Via The Motley Fool

Cathie Wood Bought More CRISPR Therapeutics Stock 2 Days in a Row. Here's What She Sees in the Biotech Stock. ↗

October 18, 2026

Billionaire investor Cathie Wood, through her ARK ETFs, made big buys of CRISPR Therapeutics on Friday, Oct. 9, and Monday, Oct. 12.

Via The Motley Fool

Topics ETFs

1 Nasdaq 100 Stock on Our Watchlist and 2 That Underwhelm

October 16, 2026

The Nasdaq 100 (^NDX) is home to some of the biggest success stories in tech and growth investing. However, certain stocks in the index face challenges like ...

Via StockStory

Forget Cystic Fibrosis: Vertex's Next Growth Engine Could Be Hormone Disorders ↗

October 15, 2026

Vertex Pharmaceuticals is showing that it isn't a one-trick pony.

Via The Motley Fool

Moderna vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? ↗

October 13, 2026

Vertex raised its full-year outlook in Q2 with a growing pipeline across multiple disease areas. Moderna’s mRNA flu vaccine just cleared a key FDA hurdle with an expanding oncology pipeline behind it.

Via The Motley Fool

2 High-Flying Stocks on Our Watchlist and 1 We Question

October 12, 2026

“You get what you pay for” often applies to expensive stocks with best-in-class business models and execution. While their quality can sometimes justify the ...

Via StockStory

Citi Sees 60% Upside in CRISPR Therapeutics. Here's What Has to Go Right. ↗

October 09, 2026

Most of any gains (or lack thereof) from here will be driven by just three factors.

Via The Motley Fool

2 Safe-and-Steady Stocks with Promising Prospects and 1 We Turn Down

October 05, 2026

A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on hi...

Via StockStory

Topics Energy

Amgen vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026? ↗

October 04, 2026

One offers a more affordable entry point while the other boasts some of the highest profit margins in the sector. The choice comes down to whether you prioritize income stability or growth potential.

Via The Motley Fool

Axsome Therapeutics vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026? ↗

October 01, 2026

Vertex dominates cystic fibrosis with expanding disease coverage and a pipeline entering new therapeutic areas. Axsome is building a commercial drug portfolio quickly but is still working toward...

Via The Motley Fool

Topics Intellectual Property

2 Wall Street Analysts Think Vertex Pharmaceuticals Stock Can Soar Another 20% or More Over the Next 12 Months. Here's Why They're Right. ↗

September 29, 2026

This biotech player is firing on all cylinders.

Via The Motley Fool

Topics Intellectual Property

2 Healthcare Stocks to Target This Week and 1 We Avoid

September 28, 2026

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Shareholders who bet on the industry...

Via StockStory

< Previous 1 2 3 4 5 6 7 8 9

...

69 70 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.